Law.com has published a profile on the impact of the coronavirus outbreak on the way premier plaintiff law firms are conducting business in this week’s Critical Mass briefing for class action and mass tort attorneys. The profile features interviews with several prominent plaintiffs’ lawyers on working through isolation. The publication notes that while so-called “Big Law” defense firms have scrambled, struggling to effectuate remote work, many plaintiffs’ firms, particularly those which had previously embraced cutting-edge technological innovations, have transitioned to a fully remote working status almost seamlessly.
The first attorney interviewed by Law.com is Lieff founding partner Elizabeth Cabraser:
“One thing that surprised me is I’m spending probably 10-12 hours a day on telephonic conferences with lawyers. We’re getting a lot done, because we don’t have anywhere to go. I have an automatic ‘time to get on an airplane’ reflex, but I haven’t been able to get on airplanes, so the inefficiencies of travel are eliminated. Everybody is in touch all the time, because we’re not on a plane for six hours with bad WiFi. It’s a revelation to me, just how inefficient all the time before was. Suddenly, there is more time to communicate with people and actually get things done. I don’t think it’s going to go back to the way it was. I don’t think it can.”
Read the Critical Mass article on the Law.com site (subscription).
About Elizabeth Cabraser
Name partner and co-founder of Lieff Cabraser, Elizabeth Cabraser chairs the firm’s personal injury and environmental litigation practice groups. One of the nation’s leading class action litigators and possessing unparalleled expertise in complex civil litigation, she has served as court-appointed lead, co-lead, or class counsel in scores of federal multi-district and state coordinated proceedings. Today, she serves in court-appointed leadership positions in several of the nation’s highest profile civil cases, including a solo leadership role in the VW “Clean Diesel” Emissions case, as well as lead positions in the GM ignition switch defect and Takata defective airbag cases, and the recently-filed Fiat Chrysler Jeep Dodge diesel emissions fraud litigation, Generic Drugs Pricing antitrust litigation, and the National Prescription Opiates litigation.